How FDA Review of Sarepta's ESSENCE Data At Sarepta Therapeutics (SRPT) Has Changed Its Investment Story [Yahoo! Finance]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Yahoo! Finance
of AMONDYS 45 and VYONDYS 53 from accelerated to traditional approvals, using data from the ESSENCE Phase 3 study and real-world evidence in Duchenne muscular dystrophy. This move, if accepted by regulators, would mark an important validation of Sarepta's exon-skipping platform and could meaningfully enhance the durability of its DMD franchise. We'll now examine how this regulatory push to convert accelerated approvals, alongside ELEVIDYS safety work, may influence Sarepta's investment narrative. Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. Sarepta Therapeutics Investment Narrative Recap To own Sarepta, you need to believe its DMD portfolio can sustain meaningful, durable demand while it manages gene therapy safety concerns and capital intensity. The latest plan to convert AMONDYS 45 and VYONDYS 53 to traditional approvals could modestly stren
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 [Yahoo! Finance]Yahoo! Finance
- Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1Business Wire
- Sarepta Therapeutics: A $2B Business Priced Like It's Broken [Seeking Alpha]Seeking Alpha
- Sarepta Therapeutics (SRPT) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $37.00 price target on the stock.MarketBeat
- Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53® [Yahoo! Finance]Yahoo! Finance
SRPT
Earnings
- 2/25/26 - Miss
SRPT
Sec Filings
- 3/13/26 - Form 4
- 3/13/26 - Form 4
- 3/13/26 - Form 4
- SRPT's page on the SEC website